Skip to Content Skip to Search

United Kingdom

Disclosure of payments made to HCPs in the UK

As part of our goal to be one of the most innovative, best performing and trusted healthcare companies in the world, we seek to meet society’s evolving expectations, bring greater transparency to an already well-regulated industry, and strengthen our relationships with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) future collaboration.

Cooperation between pharmaceutical companies, regulators, HCPs, HCOs, and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been, and will always be, valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet patient and public health needs.

Under the EFPIA Disclosure Code, from 2016 EFPIA member companies pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.

Transfer of value disclosure information is published annually (covering the previous year) on a public platform; either the company’s own website or, in some countries, a central platform combining data from different companies.

In line with EFPIA Disclosure Code, disclosure information in the UK is published annually (covering the previous year) through the Association of the British Pharmaceutical Industry (ABPI) Disclosure UK website:

Following the acquisition of Tesaro in 2019, GSK have aligned with the EFPIA Board resolution made in 2016 that in the case of a new entity (following M&A) the implementation of the EFPIA Disclosure associated with the acquisition can be implemented with a 12-month delay. Therefore all transfers of value incurred by Tesaro activity in the UK in 2019 were disclosed by Tesaro; however old Tesaro engagements were still paid in 2020, and are now included in GSK disclosure.

Our disclosures for the United Kingdom

The links below will take you to our disclosures for the UK in line with the EFPIA code and ABPI Disclosure UK data, and to a note on the methodology used to set out the data in the report.



Methodological note

2020 PDF PDF

Previous years


Methodological note

2019 PDF PDF


See Disclosure UK

See Disclosure UK

Media enquiries:
Please contact the UK Pharma Communications Team on +44 208 990 2144.